Phase 3 Trial of Pembrolizumab with Olaparib Did Not Meet Endpoints Among Individuals with NSCLC

Pembrolizumab in combination with chemotherapy followed by maintenance olaparib did not meet its pre-specified statistical criteria of overall survival or progression free survival.

Related Keywords

,Gregory Lubiniecki ,Merck Sharp Dohme ,Merck Research Laboratories ,Pembrolizumab With Maintenance Olaparib ,Maintenance Pemetrexed ,Metastatic Nonsquamous Non Small Cell Lung Cancer ,Merck Sharp ,Provides Update ,Plus Maintenance Lynparza ,